The content on this site is intended for healthcare professionals only
Dr Neal Lindeman speaks to ecancer about non-small cell lung cancer pathology.
Initially, he discusses the latest state of play in diagnostics in EGFR mutated NSCLC.
He then talks about the unmet needs and challenges in this diagnostic setting.
Dr Lindeman mentions some recommended methods for NSCLC identification and diagnostics and explains the current testing methods for EGFR uncommon mutations such as EGFR exon 20 insertions.
He concludes by talking about comprehensive molecular testing for NSCLC with EGFR mutations and what the future looks like for diagnosing this type of lung cancer.
This programme has been supported by an unrestricted educational grant from Takeda
The Vanessa Moss Prize: celebrating research into cancer health disparities
Tele-mentoring: Impact of project ECHO
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 8-14, 2023
The 5-year long-term outcomes of radiation technique for locally advanced NSCLC
Choosing Wisely in radiology Tanzania
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
Why tumour markers are not recommended as screening tests
